Zeitschrift fur Rheumatologie最新文献_第8页

Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a patient with progressive systemic sclerosis-associated interstitial lung disease : A case report and a literature review. 霉酚酸酯、尼达尼布和托珠单抗联合治疗进行性系统性硬化症相关间质性肺病1例报告和文献综述

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2026-03-05 DOI: 10.1007/s00393-026-01776-7

Liangyu Chen, Xiaoxuan Li, Donghui Huang, Peisheng Chen, Pan Xu, Huihui Chen, Xiao Zhang

引用次数: 0

[Large language models in rheumatology : New ways of knowledge transfer]. 风湿病学中的大型语言模型：知识转移的新途径。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2026-03-20 DOI: 10.1007/s00393-026-01803-7

Johannes Knitza, Thomas Hügle

{"title":"[Large language models in rheumatology : New ways of knowledge transfer].","authors":"Johannes Knitza, Thomas Hügle","doi":"10.1007/s00393-026-01803-7","DOIUrl":"10.1007/s00393-026-01803-7","url":null,"abstract":"Medical knowledge is growing exponentially in rheumatology, posing increasing challenges for knowledge dissemination among physicians, educators and patients. Traditional information and learning formats are reaching their limits in view of the rapid emergence of new clinical studies, guidelines and treatment concepts. Large language models (LLMs) offer the possibility to structure, synthesize and contextually adapt extensive and complex information within a short time. This opens new perspectives for clinical decision support, medical education, patient education and scientific work in rheumatology. This article systematically categorizes the use of LLMs across these fields of application and discusses the opportunities, risks and practical implications using selected examples that colleagues can immediately apply. Early data suggest a high potential for use and growing acceptance among physicians, students and patients; however, significant challenges remain. These include concerns regarding the validity and transparency of the generated content, potential biases, data protection issues and the risk of uncritical adoption of artificial intelligence (AI)-generated recommendations. The use of LLMs can make rheumatological knowledge rapidly, individually, and easily accessible but does not replace medical responsibility or clinical expertise. An evidence-based evaluation, clear regulatory framework conditions, safe integration into existing workflows and targeted training and governance concepts are essential to harness the potential of LLMs for knowledge dissemination in rheumatology in a sustainable and responsible manner.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"366-371"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147491889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie. “DGRH - RheumaAkademie事件”。

IF 1 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 DOI: 10.1007/s00393-026-01833-1

引用次数: 0

[Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases]. [SARD-ILD的发展管理：类风湿相关间质性肺疾病的当前挑战和新出现的治疗选择]。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2026-03-25 DOI: 10.1007/s00393-026-01807-3

Torsten Witte, Jonas Schupp

{"title":"[Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases].","authors":"Torsten Witte, Jonas Schupp","doi":"10.1007/s00393-026-01807-3","DOIUrl":"10.1007/s00393-026-01807-3","url":null,"abstract":"Background: Systemic rheumatic diseases with interstitial lung disease (SARD-ILD) are often associated with progressive pulmonary fibrosis (PPF), characterised by increasing respiratory symptoms, progressive loss of lung function, and an unfavourable prognosis. Currently available therapies, including glucocorticoids, immunosuppressants and antifibrotic agents, often have limited efficacy depending on the underlying SARD-ILD, while adverse events limit their use. Therefore, there is a substantial unmet need for effective and well-tolerated treatment options.Objectives: This review summarises current developments and emerging therapeutic approaches in SARD-ILD and PPF, highlighting their potential relevance for clinical practice.Materials and methods: A systematic PubMed search (publications up to mid-2025) using the terms \"SARD-ILD\", \"CTD-ILD\", \"PPF\" and \"treatment\" identified relevant studies investigating novel therapeutic strategies.Results: Substances currently under clinical investigation include nerandomilast, belimumab, admilparant, anifrolumab and inhaled treprostinil. Nerandomilast, a preferential PDE4B inhibitor with antifibrotic and anti-inflammatory properties, demonstrated a reduction in lung function loss and mortality risk with good tolerability in the phase‑3 FIBRONEER-ILD study, potentially representing a turning point in the management of autoimmune-associated ILD.Conclusion: Promising results from ongoing clinical studies provide new therapeutic perspectives for SARD-ILD and PPF and may significantly improve prognosis and disease burden in the future.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"382-389"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Forschungsintegrität : Herausforderungen und Lösungsansätze beim wissenschaftlichen Publizieren. 研究诚信：科学出版的挑战和解决方案。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 DOI: 10.1007/s00393-026-01828-y

Paul Herrmann

引用次数: 0

Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. denosumab生物类似药和原药治疗绝经后骨质疏松症的疗效和安全性比较：一项随机对照试验的meta分析。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2025-09-24 DOI: 10.1007/s00393-025-01737-6

Young Ho Lee, Gwan Gyu Song

{"title":"Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a meta-analysis of randomized controlled trials.","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.1007/s00393-025-01737-6","DOIUrl":"10.1007/s00393-025-01737-6","url":null,"abstract":"Objective: The study aimed to assess whether a denosumab biosimilar is as effective and safe as the original denosumab for treating postmenopausal osteoporosis.Methods: A comprehensive search of MEDLINE, Embase, and the Cochrane databases identified six randomized controlled trials (RCTs) relevant to this study. The meta-analysis focused on evaluating percentage changes in bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip, alongside monitoring adverse events (AEs), serious adverse events (SAEs), and infections.Results: The analysis encompassed 1784 patients, with 978 and 816 receiving biosimilar and originator therapy, respectively. Regarding standardized mean differences (SMDs) for BMD changes, a lumbar spine SMD of -0.048 (95% confidence interval [CI]: -0.142 to 0.046; P = 0.317), femoral neck SMD of 0.089 (95% CI: -0.068 to 0.247; P = 0.266), and total hip SMD of 0.029 (95% CI: -0.153 to 0.212; P = 0.755) were found, showing no significant differences between the two treatments. Safety profiles were also comparable, with odds ratios (ORs) of 1.168 (95% CI: 0.795-1.716; P = 0.428) for AEs, 1.120 (95% CI: 0.644-1.946; P = 0.689) for SAEs, and 1.576 (95% CI: 0.657-3.780; P = 0.308) for infections.Conclusion: The denosumab biosimilars demonstrated efficacy and safety profiles comparable to the originator in the treatment of postmenopausal osteoporosis.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"403-408"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[New biomarker-based diagnostic tests : Early and precise diagnosis of rheumatological diseases]. [新的基于生物标志物的诊断测试：风湿病的早期和精确诊断]。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2026-05-18 DOI: 10.1007/s00393-026-01821-5

Franz Thiele, Stephanie Finzel

引用次数: 0

Systemic immune-inflammation index and systemic inflammation response index in systemic lupus erythematosus: a meta-analysis. 系统性红斑狼疮的全身免疫炎症指数和全身炎症反应指数：荟萃分析。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2025-10-28 DOI: 10.1007/s00393-025-01751-8

Young Ho Lee, Gwan Gyu Song

{"title":"Systemic immune-inflammation index and systemic inflammation response index in systemic lupus erythematosus: a meta-analysis.","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.1007/s00393-025-01751-8","DOIUrl":"10.1007/s00393-025-01751-8","url":null,"abstract":"Objective: The objective of this meta-analysis was to assess the relationships of the systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI) with systemic lupus erythematosus (SLE) and to determine the correlation of these indices with disease activity as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).Methods: We performed a systematic search of Medline, Embase, and the Web of Science databases to identify eligible studies. Standardized mean differences (SMDs) were calculated to compare SII and SIRI between individuals with SLE and healthy controls. Pooled correlation coefficients were used to estimate the strength of the associations between SII, SIRI, and SLEDAI scores.Results: Eleven studies qualified for inclusion in the meta-analysis. The aggregated analyses indicated that SII was markedly higher in SLE patients than in healthy controls (SMD 0.961; 95% CI 0.632-1.291; p < 0.001), a finding that remained consistent irrespective of data type, study sample size, or lupus nephritis status. Similarly, SIRI was elevated in those with SLE (SMD 0.761; 95% CI 0.320-1.203; p = 0.001). Analysis of correlation revealed that SII had a statistically significant positive association with SLEDAI scores (correlation coefficient 0.322; 95% CI 0.146-0.478; p < 0.001), supporting its value as a marker of increased disease activity. In contrast, SIRI did not present a significant association with SLEDAI (correlation coefficient 0.133; 95% CI -0.119 to 0.369; p = 0.302).Conclusion: This meta-analysis provides evidence that both SII and SIRI are significantly increased in patients with SLE compared to healthy controls, supporting their utility as inflammatory biomarkers in SLE. Additionally, SII demonstrated a moderate positive correlation with disease activity, emphasizing its relevance for evaluating SLE severity.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"409-415"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145393765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Modern knowledge transfer in rheumatology-From the perspective of teachers]. 【风湿病学的现代知识转移——从教师的角度看】。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2026-04-20 DOI: 10.1007/s00393-026-01811-7

Arnd Kleyer, Alexander Pfeil

{"title":"[Modern knowledge transfer in rheumatology-From the perspective of teachers].","authors":"Arnd Kleyer, Alexander Pfeil","doi":"10.1007/s00393-026-01811-7","DOIUrl":"10.1007/s00393-026-01811-7","url":null,"abstract":"Rheumatology is a clinical discipline of high relevance to healthcare, yet it is often underrepresented in medical studies. The discipline combines complex immunological principles with challenging differential diagnostics and a broad spectrum of practical skills, including clinical and musculoskeletal examinations, joint ultrasound examination, invasive procedures and the interpretation of laboratory and pathology findings. As there are only a few rheumatology chairs in Germany, students have only limited contact to patients with inflammatory rheumatic diseases. Teachers also face considerable didactic and structural challenges, in particular limited curriculum time and increasing economic pressure in routine clinical practice. The aim of this article is to present the current developments in rheumatology teaching and to critically evaluate conventional and innovative teaching formats. In addition to conventional teaching methods, contemporary digital and multimodal approaches, including blended learning and augmented and virtual reality, are discussed. Particular emphasis is placed on the competence-oriented approach to teaching, the integration of skills laboratories and student participation and the practical challenges of implementation. Finally, the importance of a stronger curricular anchoring of rheumatology for recruiting young colleagues and concrete recommendations for action in the teaching practice are summarized.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"355-359"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147730317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Modern knowledge transfer from the perspective of the Rheumatism Academy]. [风湿病学会视角下的现代知识转移]。

IF 1.2 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2026-06-01 Epub Date: 2026-04-01 DOI: 10.1007/s00393-026-01808-2

Anna Julia Voormann

{"title":"[Modern knowledge transfer from the perspective of the Rheumatism Academy].","authors":"Anna Julia Voormann","doi":"10.1007/s00393-026-01808-2","DOIUrl":"10.1007/s00393-026-01808-2","url":null,"abstract":"Medical training and continuing medical education (CME) are undergoing change. Digitalization, competence orientation and changing learning habits are encountering specific challenges in rheumatology, such as chronic disease progression, interdisciplinarity and a growing shortage of young talent. Against this backdrop, institutional players in continuing education are becoming particularly important. Modern knowledge transfer in rheumatology requires a didactically sound combination of face-to-face, digital and hybrid formats. The Rheumatism Academy (Rheumaakademie) positions itself as a central, independent platform throughout the entire rheumatology career, from students to specialists. Key figures from 2024 and 2025 demonstrate the range and structure of the offers. Digital learning infrastructures, such as media libraries, social media and innovative formats for young professionals complement traditional continuing education offers. The quality of knowledge transfer continues to depend on specialized content, close networking with experts and transparent quality assurance processes. The Rheumaakademie exemplifies how professional society-affiliated organizations can support sustainable education, workforce development and high-quality patient care.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"346-354"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0